Sustained positive clinical results for autologous anti-CD19 #CARTCells in patients with moderate-to-severe generalized myasthenia gravis (Phase II trial).

In vivo #CARTCells race for autoimmune grows as two RNA startups enter the clinic. buff.ly/6Vwaz1N

Very encouraging interim data for allogeneic, off-the-shelf CAR-T (healthy donor T cells) cema-cel in 24 patients as first-line consolidation in LBCL. Licensed by Celgene to Servier, then sublicensed to Allogene. buff.ly/ETu4rW1

The turning point for rare diseases, which affect >300 million people around the world. A call to get rid of its many structural obstacles, to consider it as molecular surgery unlike drug treatments gift link: www.nytimes.com/2026/04/09/o...

John Deering

Weekly #regenerative reads: 1st FDA-approved CIRM supported therapy, asymmetric histone inheritance, stem cell retraction ipscell.com/2026/04/week... #stemcells

tl;dr: NIH is running at about 60% of pre-Trump levels and NSF is running at about 20% of pre-Trump levels of funding-outlays (some directorates far below even that). Utterly catastrophic. An unforced disaster for U.S. society, and the world

Korea establishes first clinical-grade #iPSCells bank to boost cell therapy R&D.

Join us June 23–24, 2026, Montpellier, for this first‑edition Complex Organoid Systems with Multifaceted InteraCtions Symposium. Invited speakers : Katja Wolthers | Amsterdam Simon Schäfer | Germany Céline Cougoule | Toulouse Alexandre Grassart | Lille #Organoids buff.ly/wsgMCQg

Gilead is testing a bicistronic anti-CD19/CD20 #CAR_T made with a rapid manufacturing method in a Phase III trial vs. Yescarta. Reinventing its own game-changer less than a decade after commercialization.

Marthe Gautier, découvreuse oubliée du chromosome de la trisomie 21 : l'effet Matilda. Le Journal du CNRS. lejournal.cnrs.fr/articles/mar...

A headline like this would have seemed absurd to me a year ago and it sounds mundane today. What I see happening at work is so advanced, I just hope someday we either publish outcomes or productize what we’re doing.

“Air pollution fell substantially as Paris restricted car traffic and made way for parks, people-streets and bike-lanes.” Better for the climate, better for health, better for livability and quality of life. Common sense. Such a no-brainer, it’s remarkable that more cities HAVEN’T done the same.

A video shows improvements in hearing in a child who received gene therapy for 𝘖𝘛𝘖𝘍-related deafness. Watch the full video and read the accompanying article: nej.md/4o7ky8f #MedSky

Enshittification, here we come!

A gene-editing method generates immunotherapeutic CAR T cells in the body @nature.com @j-eyquem.bsky.social @ucsfhealth.bsky.social @ki.se www.nature.com/articles/d41... @heidiledford.bsky.social www.nature.com/articles/d41... www.nature.com/articles/s41...

‼️ We are on track for a staggering 98% reduction in posted NIH funding opportunities this year relative to historical norms. Political review and red tape are blocking approval of funding announcements across the board. See Elizabeth Ginexi’s analysis: elizabethginexi.substack.com/p/i-wrote-re...

Positive Phase I/II results from Aspen using autologous #iPSCells-derived dopaminergic neuron precursors for surgical treatment of Parkinson’s disease. Pivoting to phase III. Very promising! buff.ly/Z6ItRnM

All three lines are correct and true representations of reality. Data literacy is a crucial skill to make sense of the world.

BioNTech co-founders to exit company and start a new one buff.ly/y8vK8nh

Pas de CASGEVY en France (CRISPR/Cas9 pour la Bêta Thalassémie et la Drépanocytose)?

China approved a gene therapy at 1/10 the price of its U.S. rival. China is poised to rapidly disrupt the gene and cell therapy field. buff.ly/CfZDNgS

Nature comment: two first #iPSCells medicines got conditional approval after treating only 7–8 patients Smart acceleration or risky precedent? buff.ly/2PgcKWj

📣 📣 📣 World first!! Japan’s health ministry has granted a provisional 7-year approval for the commercialization of two regenerative medicine products derived from #iPSCells, aimed at treating ischemic cardiomyopathy and Parkinson’s disease. buff.ly/nAKKmib

Merci à Nicolas Henin pour ce fil qui vous explique comment changer de Blue en Eurosky

It’s a really weird time in tech. You’re excited at the idea that AI coding agents are making people 20% - 200% more productive but also know the bean counters are asking if that means they can get away with 2%-20% layoffs.

This is also a very good reason to completely abandon American big tech and their utterly corrupt leaders who only want to enrich themselves. This article gives an overview of 20 European Alternatives to Major US Technology Services. Europe has had more than enough of this disgusting mafia gang!

Complex structural variations and rearrangements in cancer are identified using long-read sequencing go.nature.com/3R334eH rdcu.be/e5kOO

AI agents have caused a sea change in programming, going from hype to reality last December. That Claude takes English instructions to build apps, configure settings, and self-correct errors is magical to behold. It’s easy to dismiss without trying the latest models, but code is effectively free.

Wow. That’s really heartbreaking. Failing to find a buyer, BioMarin pulls Roctavian in gene therapy's biggest disappointment

First test of gene therapy for a rare form of autism is underway. Jaguar Gene Therapy dosed the first child a year ago and has since treated four more, all between the ages of 2 and 4, diagnosed with Phelan-McDermid syndrome (SHANK3 mutations). buff.ly/UooaRDV

Gilead to acquire cell therapy partner Arcellx for $7.8B. At the center of the buyout is anito-cel, which is the multiple myeloma CAR-T cell therapy that Gilead and Arcellx are already developing together. The treatment is expected to be a safer option.

😕

The strongest version of this illusion I’ve seen! Absolute head-wrecker!

Review: Viral genome editing methods and applications in the CRISPR era journals.asm.org/doi/10.1128/...

A first-in-human #GeneTherapy clinical trial is being launched to evaluate partial cellular reprogramming of the eye using AAV delivery of OCT4, SOX2, & KLF4 under doxycycline control, targeting two forms of age-related vision loss. Based on the work of David Sinclair (Harvard). buff.ly/uV4kbgU

"This is the hard truth I want to land: climate does not care what’s trending. It’s not interested in Jeffrey Epstein, Gaza, or Greenland. There is no algorithmic mercy. Physics is physics, and it is getting more abrupt." #climatecrisis #ElNino #auspol www.lyrebirddreaming.com/post/we-are-...

D. Mionet #Geopolitis manque terriblement 😭 si quelqu'un a des nouvelles parmi vous je suis preneur...

FDA reflections on #CARTCells therapies and autoimmunity: the key challenge is finding the match between the right product and the right indication. www.fiercebiotech.com/biotech/fda-...

Nature and Science journalists denied entry to event featuring NIH Director

I love this!

A scaffold-free bioprinting approach achieves physiological cell densities, and is used to print in vitro models of heart and liver structures, and neural circuits #NBThighlight www.cell.com/cell/fulltex...

[AI companies will fail. We can salvage something from the wreckage | AI (artificial intelligence) |The Guardian] “AI is asbestos in the walls of our tech society, stuffed there by monopolists run amok. A serious fight against it must strike at its roots“ www.theguardian.com/us-news/ng-i...

Another major triumph for a refractory autoimmune disease—hemolytic anemia—through engineered T cells @nejm.org nejm.org/doi/full/10....

Ludovic Vallier, Stem Cell Reports Associate Editor, is attending Biotherapy Days 2026 in Toulouse, France 28-30 January 2026. Connect with him to discuss whether your research is a fit for publishing in Stem Cell Reports!

2025 was the hottest year on record for ocean heat content. Unfortunately, we now say this every year. 🥹 "In addition to setting a new record in 2025, the global ocean continues to show sustained and intensified warming." + #OpenAccess Study: doi.org/10.1007/s003... + Data: www.ocean.iap.ac.cn

Other data regarding #CARTCell treatments in France. Interesting! Source : buff.ly/k3Z9kDv

Number of #CARTCell treatments in France : rapidly increasing. Source : buff.ly/k3Z9kDv

Solid tumor, allogeneic #CART alert 📣 : encouraging results from a phase I study using allogeneic IL-13Rα2 CAR-T cells in five people with recurrent high-grade glioma. buff.ly/Q8RBlx4